Drug Pricing Reform and Market Access: Why Lower Prices Won’t Simplify Access

Drug pricing reform and market access are becoming increasingly interconnected, but lower prices do not remove the decisions that ultimately determine whether a therapy achieves meaningful access.

Medicare negotiation, Most-Favored-Nation pricing initiatives, and other affordability efforts are reshaping the economics of pharmaceutical commercialization. The latest MFN agreements announced on August 31 bring additional manufacturers into pricing arrangements tied to prices in other developed markets, while CMS continues to develop the operational framework for negotiated Medicare prices.

For market access teams, the implications extend well beyond the price itself.

Health plans still need to determine where therapies belong within formularies and treatment pathways, which patients should receive them, what evidence supports differentiation, and where utilization management is appropriate.

Manufacturers still need to demonstrate clinical and economic value in increasingly competitive categories.

As pricing flexibility narrows, those decisions may become more consequential rather than less.

Price Is One Component of Access

Price has always been an important part of payer decision-making, but it exists within a broader assessment of value.

Payers evaluate therapies in the context of available alternatives, clinical outcomes, evidence quality, patient populations, budget impact, treatment sequencing, utilization patterns, and expected real-world performance. Even when the acquisition cost of a product changes, those considerations do not disappear.

The managed care community is making that point explicitly. In its August comments on Medicare drug price negotiation, AMCP supported efforts to improve affordability while emphasizing the continued importance of evidence-based formulary management, utilization management, competition, and clinical decision-making.

That distinction matters for manufacturers.

A lower price may alter the economic equation, but it does not automatically establish preferred positioning or remove access restrictions. Products still have to earn their place within an increasingly complex treatment landscape.

Evidence Becomes More Important When Pricing Flexibility Narrows

Historically, manufacturers have been able to use a combination of clinical differentiation, evidence, pricing, rebates, and contracting strategy to influence access.

As policy places greater constraints on some of those economic levers, the relative importance of evidence may increase.

Manufacturers will need to understand which attributes genuinely matter to decision-makers and whether their evidence package demonstrates those attributes clearly enough to influence coverage and utilization decisions.

That may include traditional clinical endpoints, but increasingly it can also involve real-world outcomes, comparative effectiveness, budget impact, patient journey data, adherence, treatment persistence, resource utilization, and evidence that helps identify the patients most likely to benefit.

The strategic objective is not simply to produce more evidence. It is to understand which evidence will change the access decision.

Competitive Differentiation Will Still Matter

Pricing reform also does not eliminate competition within therapeutic categories.

Payers frequently evaluate multiple products that offer meaningful clinical benefit, and the differences between those therapies may be relatively nuanced. They still need a framework for determining preferred products, sequencing therapies, defining utilization criteria, and managing overall category spend.

For manufacturers, this means competitive intelligence needs to extend beyond product profiles and list prices.

Market access teams need to understand how payers perceive competing value propositions, where evidence creates meaningful differentiation, which restrictions are likely to remain, and what could cause positioning to change as new therapies or data enter the market.

Those insights should inform development decisions well before the product reaches formulary review.

Utilization Management Is Not Going Away

One of the most important implications of the current pricing environment is that affordability reform should not be interpreted as the end of utilization management.

Payers still have a responsibility to manage clinical appropriateness and healthcare spending across populations. Prior authorization, step therapy, treatment sequencing, eligibility criteria, and other access controls can remain relevant even when the price of a therapy changes.

For manufacturers, the question becomes whether the evidence strategy anticipates those controls.

If a payer is likely to restrict a therapy to a specific patient population, manufacturers need to understand the rationale early enough to address it through evidence development, value communication, or access strategy.

Waiting until a policy is published can significantly reduce the available options.

Drug Pricing Reform and Market Access Require More Dynamic Planning

The pace of policy change is another important consideration.

CMS issued draft guidance in July describing how manufacturers will effectuate Maximum Fair Prices for selected drugs in 2028, including processes involving dispensing entities, Part B providers, and the Medicare Transaction Facilitator. Public comments remain open through September 18, 2026.

At the same time, MFN agreements continue to expand. On August 31, the White House announced agreements with nine additional pharmaceutical manufacturers, bringing the stated total to 26 manufacturers.

These developments illustrate why market access strategy cannot be treated as a static launch deliverable.

Teams need mechanisms for continually reassessing payer expectations, competitive positioning, evidence requirements, pricing assumptions, and operational implications as the external environment changes.

The assumptions used six months ago may no longer support the decision being made today.

Building Value Beyond Price

Drug affordability will remain a central policy issue, and manufacturers should expect continued pressure on pharmaceutical pricing.

But access decisions will continue to involve much more than price.

The organizations that adapt most effectively will be those that understand where value can still be differentiated, identify payer concerns early, develop evidence around the questions that matter, and continuously validate their strategies against current market conditions.

Pricing reform changes the economics of access.

It does not remove the need for market access strategy. If anything, it raises the importance of understanding exactly why a payer should choose, position, and support a therapy when price is no longer the only—or even the most flexible—lever available.

If your team is reassessing evidence, pricing, payer strategy, or launch planning in response to the changing policy environment, connect with an eMAX Health Systems market access expert: CONTACT US.